This article was originally published on December 22 for TPT members. We have been covering Lexicon Pharma (NASDAQ:LXRX) for five years now, and I invested in May 2022, took profits and am holding on ...
Lexicon Pharmaceuticals recently gained FDA approval for its heart failure and type 2 diabetes drug, Inpefa, and is marketing the drug aggressively. Lexicon's financials show mixed results, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback